Abstract Body (Do not enter title and authors here): Background: Natriruetic peptide (NP) screening is recommended for HF prevention in diabetes mellitus (DM), with NT-proBNP >125 pg/mL considered abnormal. However, evidence supporting this threshold is derived primarily from shorter-term studies. Lifetime risk (LTR) estimates for HF across NT-proBNP concentrations in DM is unknown.
Methods: Participant-level data from 6 prospective cohorts (ARIC, MESA, CHS, FOS, FHS Generation 3, CRIC) and the Look AHEAD trial control group were pooled excluding participants with prevalent HF or ASCVD at baseline. Participants were stratified according to well-established NP thresholds (Figure). LTR of HF was determined at different index ages using the pratical incidence estimator macro with modified Kaplan-Meier methods that uses age as a time scale and mortality as a competing risk. A positive control group of adults with DM and prevalent CVD was analyzed separately.
Results: Among 5,986 participants (age 61 y, 45% male, 25% Black), 1,134 developed HF over 79,347 person-years (14.3 per 1,000 person-years). At index age 55 y, the LTR of HF through 90 years was 34.4%. Lifetime risk of HF increased progressively across increasing NT-proBNP categories at each index age (Figure 1A and 1B). At index age 55 y, the LTR estimate for the NT-proBNP >125 pg/mL category (48.7%) was comparable to the positive control group with prevalent CVD (n = 1,687; 51.7%). LTR of HF was higher in Black (vs. non-Black) adults at every category with detectable NT-proBNP and was comparable to prevalent CVD at lower thresholds (50-125 pg/ml) (Figure 1B). LTR of HF among adults with low short-term HF risk (based on WATCH-DM or 10-y HF PREVENT risk scores) and NT-proBNP >125 pg/mL was high and comparable with the prevalent CVD group. Adding NT-proBNP to 30-year PREVENT HF risk score substantially improved LTR prediction performance (AUROC for 30-year risk: 0.569 to 0.685, p<0.001).
Conclusions: In adults with DM, higher NT-proBNP concentrations identify higher LTR of HF, with the highest risk noted among those with concentrations >125 pg/ml supporting the current guideline recommended screening thresholds to discriminate lifetime risk. Lifetime risk of HF associated with NT-proBNP concentrations vary by race with disporporationtely high risk observed among Black adults.